A multinational, randomised, double-blind, placebo- and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50microg, 100microg, 200microg) of BEA 2180 BR to tiotropium 5microg, delivered by the Respimat inhaler and placebo in patients with chronic obstructive pulmonary disease.

Trial Profile

A multinational, randomised, double-blind, placebo- and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50microg, 100microg, 200microg) of BEA 2180 BR to tiotropium 5microg, delivered by the Respimat inhaler and placebo in patients with chronic obstructive pulmonary disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2013

At a glance

  • Drugs BEA 2180-BR (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2009 Additional location identified as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 1950 to 2080 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top